Cara Therapeutics Secures $19 Million In Series C Financing Cara Therapeutics, Inc. announced today that it had closed on $19 million of its Series C financing. New investors participating in the round include MVM Life Science Partners and Alta Biopharma Partners, as well as previous investors
Tripos and Cara Therapeutics Announce Medicinal Chemistry Partnership; Alliance to Address Unmet Medical Needs in the Treatment of Pain and Inflammation Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, today announced that Tripos
Cara Therapeutics Announces Results of Phase 1 Clinical Trial of Novel Analgesic Cara Therapeutics, Inc. today announced results of a Phase 1 clinical trial for its peripherally acting kappa opioid agonist, CR665, under development for the treatment of postoperative pain.
Cara Therapeutics Initiates Clinical Trial of Novel Pain Drug Candidate Cara Therapeutics, Inc. announced today that it had initiated dosing in a Phase 1 clinical trial for CR665, its novel drug candidate for the treatment of postoperative pain. The single-dose protocol is scheduled to be completed